All In Biotech

Drug Trial Radar · NCT00843934

Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Randomized Controlled Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Oct 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

450

Planned (sponsor's estimate)

Start

Mar 2009

Primary completion

Dec 2012

Study completion Feb 2015

Sponsor

Lead sponsor
Nihon UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of cisplatin (CDDP) and epirubicin (EPI) in the treatment of transcatheter chemoembolization for Hepatocellular Carcinoma (HCC).

Conditions

  • Carcinoma, Hepatocellular

Interventions

  • epirubicinDrug

    Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.

  • CisplatinDrug

    Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. response rateTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Digestive Surgery, Nihon University School of Medicine

    tabashi City, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.